- 180 Life Sciences is a clinical-stage biotechnology company developing anti-tumor necrosis factor (“TNF”) therapies to treat a variety of inflammatory conditions.
- Phase 2b/3 clinical trials on fibrosis and inflammation-causing TNF irregularity are currently underway with first results expected in 2021
- The company is to be acquired by a SPAC (NASDAQ: KBLM) (NASDAQ: KBLMR) (NASDAQ: KBLMW) and will be listed on the Nasdaq Capital Market under ticker symbol ATNF
Pioneering biotech company, 180 Life Sciences Corp. is bringing hope to sufferers of Dupuytren’s Disease and other inflammatory conditions caused by an impaired immune system. Currently, the company has three major programs underway focused on therapies for separate areas of inflammation. These programs are headed by a team of renowned scientists who have already developed blockbuster drugs, discovered an entire drug class and made ground-breaking discoveries in their fields. The programs are exploring therapies expected to bring relief to those afflicted by a variety of TNF conditions, including ‘frozen shoulder,’ Dupuytren disease, postoperative cognitive dysfunction (“POCD”), and non-alcoholic fatty liver disease (“NAFLD”).
TNF is one of those good things, a surfeit of which, can turn out bad. A protein released by white blood cells to mobilize the body’s defenses, i.e. the immune system, TNF plays an essential role in fighting off diseases of many kinds. TNF triggers inflammation to create an environment conducive to healing infected or damaged tissue. Typically, this state of affairs continues just long enough to repair damage to the cells. Regular or acute inflammation lasts for a short time, going away within hours or days. But sometimes, TNF sets the inflammatory process in motion when there’s no threat, a situation that can persist for a lengthy period, leading to what is known as chronic inflammation. Chronic inflammation opens a Pandora box of ailments. Conditions linked to chronic inflammation include Alzheimer’s disease, asthma, cancer, diabetes, heart disease, and a number of others that 180 Life Sciences Corp. is currently conducting research on.
The Company’s Three Research Programs Are:
The fibrosis and anti-TNF program, based at the Kennedy Institute, University of Oxford, U.K.
The program is addressing four critical areas of inflammation:
- Dupuytren disease, a debilitating condition that causes the fingers to irreversibly curl toward the palm. Dupuytren disease affects some 15 million Americans over the age of 35, about 5 percent of the U.S. population, according to a 2014 CDC study (https://ibn.fm/1G2pt). Top line data from Phase 2b/3 trials are expected by Q4 2021.
- Frozen shoulder is a musculoskeletal impairment that makes it difficult or impossible to move the shoulders (https://ibn.fm/UBzDz). Phase 2b trials are set to begin Q3 2021.
- POCD affects patients, particularly older ones, after surgical operations. In one study, roughly 12 percent of patients over age 60 had postoperative cognitive dysfunction, three months after surgery (https://ibn.fm/fuIDp). Phase 2 trials in POCD are anticipated to commence in Q4 2021.
- Nonalcoholic steatohepatitis (“NASH”) is a type of non-alcoholic fatty liver disease, aggravated by hepatitis (https://ibn.fm/hxhA5). Preclinical studies in liver fibrosis and NASH are set to begin in late 2020.
Synthetic CBD Analogs (“SCAs”) – Preclinical – based at the Hebrew University of Jerusalem
The SCA program is based at the Hebrew University of Jerusalem, in Israel, with additional research and trials at the Kennedy Institute, at the University of Oxford.
180 Life Sciences is aiming to develop SCAs that are safe and non-psychoactive and formulated to improve efficacy, as an alternative to naturally occurring cannabidiol (“CBD”). The program is led by a team that includes Professor Raphael Mechoulam, the first to ‘discover’ tetrahydrocannabinol (“THC”). 180 Life Sciences is aiming to create a compound that is 99.5% pure CBD, which will drastically improve medical prescriptive precision. The program is also exploring a drug delivery platform—ProNanoLipospheres (“PNL”)—to improve bioavailability.
The α7nAChR program, based at Stanford University in the US.
The α7nAChR program is searching for an effective therapy to treat ulcerative colitis in ex-smokers. α7nAChR is a nicotine receptor and is a central factor in the body’s method of controlling inflammation.
180 Life Sciences Corp. is to be acquired by KBL Merger Corp. (NASDAQ: KBLM) (KBL Merger Corp. Rights NASDAQ: KBLMR) (KBL Merger Corp. Warrant NASDAQ: KBLMW), a Special Purpose Acquisition Corporation (SPAC), after which the combined entity will be listed on Nasdaq under the ticker symbol: ATNF.
NOTE TO INVESTORS: The latest news and updates relating to 180 Life Sciences are available in the company’s newsroom at http://ibn.fm/180
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.